GAL-101 has been tested extensively in preclinical models of glaucoma, such as the Morrison rat model, which has prolonged elevation of IOP following acute episcleral vein occlusion with hypertonic saline. In control animals, this elevated IOP caused about 20% of RGCs to die in 3-16 weeks, whereas less than 1% of RGC’s died in animals treated with GAL-101, whether administered via eye drops (2%, 3µL), subcutaneous (60-240 mg/kg) or intravitreal (0.1 mg/ml, 3 µL) injection (Fig. 5). In repeat experiments, independent laboratories reproducibly obtained 90-95% neuroprotection, with good correlation to reduced optic nerve degeneration despite the elevated IOP, but GAL-101 had no effect on the IOP in the animals. Taken together, the GAL-101 animal data are scientifically rigorous and robust substantiation of the unique Aβ-targeting mechanism of action of GAL-101 and its promise for neuroprotection in glaucoma.